Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

Florence Ranchon1, Gilles Salles2, Hans-Martin Späth3, Véranne Schwieritz4, Nicolas Vantard4, Stéphanie Parat4, Florence Broussais5, Benoît You6, Sophie Tartas7, Pierre Jean Souquet8, Claude Dussart9, Claire Falandry6, Emilie Henin10, Gilles Freyer6 and Catherine Rioufol11*

Abstract

Background: In spite of increasing efforts to enhance patient safety, medication errors in hospitalised patients are still relatively common, but with potentially severe consequences. This study aimed to assess antineoplastic medication errors in both affected patients and intercepted cases in terms of frequency, severity for patients, and costs.

Methods: A 1-year prospective study was conducted in order to identify the medication errors that occurred during chemotherapy treatment of cancer patients at a French university hospital. The severity and potential consequences of intercepted errors were independently assessed by two physicians. A cost analysis was performed using a simulation of potential hospital stays, with estimations based on the costs of diagnosis-related groups.

Results: Among the 6,607 antineoplastic prescriptions, 341 (5.2%) contained at least one error, corresponding to a total of 449 medication errors. However, most errors (n = 436) were intercepted before medication was administered to the patients. Prescription errors represented 91% of errors, followed by pharmaceutical (8%) and administration errors (1%). According to an independent estimation, 13.4% of avoided errors would have resulted in temporary injury and 2.6% in permanent damage, while 2.6% would have compromised the vital prognosis of the patient, with four to eight deaths thus being avoided. Overall, 13 medication errors reached the patient without causing damage, although two patients required enhanced monitoring. If the intercepted errors had not been discovered, they would have resulted in 216 additional days of hospitalisation and cost an estimated annual total of 92,907 €, comprising 69,248 € (74%) in hospital stays and 23,658 € (26%) in additional drugs.

Conclusion: Our findings point to the very small number of chemotherapy errors that actually reach patients, although problems in the chemotherapy ordering process are frequent, with the potential for being dangerous and costly.

Background

The report, “To Err is Human”, from the Institute of Medicine estimated that between 44,000 and 98,000 patients die each year in the USA as a result of medical errors [1]. Although certain adverse events are unavoidable, many are preventable, with medication errors being a major cause of such accidents [2]. Medication errors may occur anytime and at any stage during the medication use process, from the prescription of the drug to its preparation, dispensing, and final administration to the patient. Moreover, the medication process involves the whole medical team, involving physicians, pharmacists, and nurses [3].

Medication errors with antineoplastic drugs may be catastrophic due to the drugs’ high toxicity and small therapeutic index in addition to the health status of cancer patients. A study revealed that antineoplastic agents were the second most common cause of fatal medication errors [4]. While overdosage is likely to result in permanent damage to the patient, underdosage may compromise the success of therapy. Although several individual case reports focused on medication errors...
At present, the prevention of antineoplastic medication errors is a priority in hospitals [13], with numerous recommendations being published in order to help decrease the likelihood of errors [14-16]. The emerging patient safety movement advocated a shift from the historical culture of blame and shame to a culture of transparency in order to encourage health care workers to report their errors [17]. Consequently, national reporting systems for medication errors were established, but as these were not mandatory, the published errors tended to reflect only a small proportion of the actual errors committed. Little data is available on the potential severity and clinical consequences of antineoplastic medication errors in terms of the need for enhanced patient monitoring, new or prolonged hospitalisation, and initiation of new treatments. Medication errors are costly to patients, their families, and employers, as well as to hospitals, health-care providers, and insurance companies, although there are few reliable estimates of their costs [18,19].

In order to reduce medication errors, we must increase our awareness about their occurrence and consequences. Thus, we conducted a 1-year prospective study aimed at detecting antineoplastic medication errors in both affected patients and intercepted cases in terms of frequency, severity for patients, and economic impact on the French Public Health Insurance.

**Methods**

**Setting**

The study was conducted in a 1200-bed teaching hospital in France. During the 1-year study, the centralised cytotoxic preparation unit set up approximately 21,000 doses of antineoplastic agents for patients in the haematology, medical oncology, and pneumology wards, as well as other units involved in the care of cancer patients. Wards included both daycare and inpatient units. The age, experience, and status of prescribers varied, ranging from residents to senior attending physicians. The medical data system was not fully computerised as prescriptions were handwritten on standardised forms, entered into a local database, and then transferred to the pharmaceutical unit in order to be verified by pharmacists. In addition, all forms were validated by senior physicians and pharmacists. Physicians had to approve the prescription, providing a signed “green light” for both cytotoxic drug preparation and administration, indicating that they thought patients were able to receive the treatment according to their daily clinical and biological status (blood count, etc.). Pharmacists had to analyse prescriptions by verifying patient data (identity, age, weight, and height) as well as the antineoplastic regimen to be used, and then entering the data into dedicated pharmacy software (Asclepios®). In addition, pharmacists confirmed any dose adjustment or deviation from the validated antineoplastic regimen. The software calculated other data, namely body surface area, anticancer drug dose, date and time of prescription, as well as day and duration of drug delivery to the patient. Fabrication forms that permitted the preparation of anticancer drugs by pharmacy technicians were also edited, including a double check at each step of the fabrication process. Prior to dispensing prescriptions to medical wards, for each preparation, pharmacists carried out a qualitative control by verifying the patient’s name, drug dose, and type and volume of dilution fluid in addition to a semi-quantitative control by comparing the ordered dose and number of vials used.

**Detection of medication errors**

Our prospective study undertaken between June 2006 and May 2007 aimed to collect all antineoplastic medication errors, concerning both unintercepted mistakes that affected patients and intercepted mistakes. Medication errors were defined as a failure in the treatment process, which led to or had the potential to lead to the patient being harmed. The different types of medication errors are defined in Table 1. During routine practice, errors were able to be detected and intercepted at every step of the chemotherapy process, with all health professionals being involved in error detection. Prescription errors were detected by pharmacists using systematic pharmaceutical analysis of all prescribed antineoplastic regimens. Preparation errors were detected during the preparation by the double checked of the fabrication process and by self-reported by pharmacy technicians, or at the time of final pharmaceutical control. Finally, administration errors were reported on a voluntary basis by nurses or physicians.

**Analysis of potential clinical consequences**

For each intercepted medication error, the potential severity was evaluated according to the Medication Error Index for categorising such errors, ranging in severity from “no patient harm” to “potential patient death” [3]. A literature review on chemotherapy medication errors and their consequences was performed using Pubmed database, with the search keywords being “antineoplastic agents and overdoses” and “antineoplastic agents and medication errors”. An analysis of case reports allowed us to design a worksheet aimed to assess the potential clinical consequences arising from anticancer medication errors in terms of the need for enhanced patient monitoring, hospitalisation (number and duration of hospital stays), or initiation of new treatments (Table 2). The potential severity and consequences of
the avoided errors were assessed and scored independently by two physicians specialised in haematology, oncology, and pneumology according to the case. Based on our analysis of actual prescription charts and error descriptions, the assessment of the potential damage of each error took into account individual patient history and pharmacological data regarding the risk of adverse events. Two pharmacists analysed the remaining intercepted medication errors that did not have any impact on patients.

Cost simulations
Cost was defined as the hospital costs incurred by the French public health insurance system in order to treat

Table 1 Classification of medication errors

| Type of medication errors          | Definition                                                                 |
|-----------------------------------|---------------------------------------------------------------------------|
| Prescription errors               |                                                                           |
| Error linked to the choice of antineoplastic regimen | Difference of antineoplastic regimen compared to the previous cycle or the multidisciplinary medical decision |
| Dose error                        | Under- or overdosage of more than 5% of antineoplastic drugs (calculation mistake or omission of dose reduction when dosage adjustment was required) |
| Incomplete prescription           | Missing data on the prescription, such as patient identity, anthropometric or biological data, drug dose, prescriber's signature, and date of administration |
| Cancellation of medical approval  | Misinterpretation of the clinical status of the patient, who was not able to receive chemotherapy |
| Pharmaceutical errors             | Errors in pharmaceutical analysis (i.e., pharmacist-generated mistakes or failure to detect prescription errors), data entry in the pharmaceutical software, preparation, storage, or dispensing errors |
| Drug administration errors        | Any discrepancy between the physicians’ chemotherapy orders and drug delivery to the patient, such as timing errors, omission, unordered drug, wrong route, wrong patient, deteriorated drug, and technical error in administration (e.g., wrong infusion flow rate) |

Table 2 Worksheet used to assess the potential clinical consequences due to anticancer medication errors

| Error number: | Check the appropriate boxes | Physician assessment number: 1 or 2 | Potential severity according to the Medication Error Index (3) | Potential clinical consequences | Potential hospitalisation and treatment* |
|--------------|-----------------------------|-------------------------------------|--------------------------------------------------------------------------------|-------------------------------|------------------------------------------|
|              |                             |                                     | No consequences for the patient                                                                                                   |                               |                                          |
|              |                             |                                     | An error avoided that would not cause patient harm                                                                                |                               |                                          |
|              |                             |                                     | An error avoided that would require monitoring to confirm that it did not result in patient harm                                   |                               |                                          |
| Temporary damage |                               |                                     | An error avoided that could have contributed to temporary harm to the patient, requiring intervention                              | Acute renal failure           | Hospitalisation                          |
|              |                             |                                     | An error avoided that could have contributed to temporary harm to the patient, requiring initial or prolonged hospitalisation | Vomiting                      |                                          |
| Permanent damage |                             |                                     | An error avoided that could have contributed to permanent patient harm                                                           | Hepatic cytolysis             |                                          |
| Compromised vital prognosis |                             |                                     | An error avoided that could have required intervention necessary to sustain life                                                 | Diarrhea                      |                                          |
| Patient death |                             |                                     | An error avoided that could have contributed to the patient’s death                                                                 | Other:                        |                                          |

* Only drugs funded in addition to the diagnosis-related groups costs
the victims of antineoplastic medication errors. In theory, these resources would not have been required had there been no error. Three scenarios were thus possible:

1- The chemotherapy medication error would have been without clinical consequences for the patient, and without economic consequences for the hospital.

2- The chemotherapy medication error would have resulted in clinical consequences for the patient, requiring out-of-hospital treatment, but without economic consequences for the hospital (for example, a minor overdosage of vincristin causing peripheral neurotoxicities, which might be treated at home using analgesics).

3- The chemotherapy medication error would have resulted in clinical consequences for the patient, requiring hospitalisation and treatment. In this case, hospital stays depending on potential consequences of medication errors as estimated by physicians were simulated using GHIM software (Hospital and medical information management) based on the diagnosis-related groups of the French medical hospital information system. These simulations were conducted according to established guidelines [20]. The costs of expensive drugs, which were funded by the French public health insurance system, in addition to costs from diagnosis-related groups were taken into account.

Statistical analysis
For the descriptive analysis of medication errors, the unit of analysis was the number of errors, with a prescribing medication order containing one or more drugs considered to correspond to one or more medication errors. The unit of analysis for assessing severity and costs was the prescribing medication order.

Univariate analysis was conducted using the Chi-squared test in order to compare the number of medication errors in relation to the month of the year or medical ward. The reliability of physicians’ judgments was calculated using Kappa statistics [22], with all statistical analyses being performed using SPSS®.

Results
Chemotherapy medication errors: incidence and type
During the 12-month study period, the pharmacy unit received 6,607 prescriptions corresponding to 22,138 distinct anticancer drugs. In total, 449 medication errors were detected throughout the medication use process, involving 341 prescriptions (Table 3). The overall medication error rate was 5.2%. Among the 449 medication errors, 436 were intercepted by physicians, pharmacists, or nurses prior to administration, while 13 reached the patients (2.9% of all errors). Medication errors were made by residents (50.7%), residents with approval by a senior oncologist (19%), and senior physicians (30.3%).

Approximately 91% (408/449 errors) of medication errors concerned inadequate prescriptions, with 405 being intercepted. Overall, 31 errors were linked to the choice of antineoplastic regimen (7.6%). In 196 cases, prescriptions were incomplete with data missing from the prescription (48%), while in 167 cases, erroneous medication doses were recorded (40.9%). The most common causal drug was carboplatin, which was involved in 35 cases or 21% of dose errors, despite corresponding to only 3% of anticancer drugs prescribed at our institution. The most prescribed drug, 5-fluorouracil, was involved in 12% of all prescriptions and represented 11% of dose errors (19 cases), while oxaliplatin represented only 2% of prescriptions, but was the third most common drug involved in dose errors (8% or 13 cases) (Table 4). In 14 cases (3.4%), the physician requested the drug preparation process to be stopped in order to further analyse the patient’s status despite previously giving medical approval.

Overall, 36 pharmaceutical errors occurred, involving 0.16% (36/22,138) of all anticancer drugs prepared, with 30 errors being intercepted. Pharmaceutical errors were classified as resulting from pharmaceutical analysis (4), data entry into the pharmaceutical software (4), preparation (26), storage (1), or dispensing errors (1).

Five errors of drug administration were reported by nurses or physicians, or 0.02% (5/22,138) of all anticancer drugs given to patients, with only one error being intercepted just prior to administration.

A statistically significant relationship was found between the rate of medication errors and month of the year (p = 0.001). May and January were the months most at risk of errors, while October and November were the least (Figure 1). When taking into account medical wards, error rates were significantly lower in haematology and medical oncology (p = 0.001, Table 3).

Medication errors: severity
In total, 341 erroneous prescriptions were reported, with 329 being intercepted. For 191 of the erroneous prescriptions considered to be without impact, the potential severity was assessed by the pharmaceutical team. The remaining 138 cases of intercepted prescriptions (41.9% of erroneous protocols) were analysed by two independent physicians from the haematology, oncology including gastroenterology and radiotherapy, and pneumology wards (Table 5). The concordance of medical judgement was found to vary depending on the medical speciality, being good in haematology (k = 0.75, 53 prescriptions), but moderate in oncology (k = 0.51, 48 prescriptions) and pneumology (k = 0.42, 37 prescriptions). Overall, 81.4% of intercepted medication errors would have had no impact for the patients. However, 13.4% of errors would have resulted in temporary damage and 2.6% in permanent injury, while 2.6% would have compromised the vital prognosis of the patient. The potential injuries
from medication errors would have varied, with 40 cases of haematological toxicity, 27 of neurotoxicity, six of hepatic cytolysis, nine of renal failure, three of skin toxicity, and two of cardiac toxicity being avoided. If not intercepted, between four and eight medication errors would have resulted in the patient’s death. These avoided incidents related to eight overdosages and one wrong route of administration. The drugs involved in the averted fatal overdosages were vinblastine (592.5 mg prescribed instead of 9.48 mg), vinorelbine (300 mg instead of 30 mg), cisplatin (1,344 mg instead of 134 mg, a daily dose of 92 mg instead of 34 mg for 5 successive days), doxorubicin (415 mg instead of 41.5 mg), and docetaxel (918 mg instead of 85.5 mg). In addition, two cases of ten-fold dose errors were intercepted with the prescription of 1,830 mg of etoposide instead of 183 mg and 1,830 mg of cisplatin instead of 183 mg. The wrong administration route error concerned the erroneous intrathecal administration of intravenous vincristine, which was intercepted just in time in the medical ward.

A total of 13 medication errors reached patients. One of these errors required enhanced monitoring of a diabetic patient, after administering anticancer preparations with a glucose solvent. Another error impacted anticoagulant treatment without any injury to the patient. The remaining errors had no consequences for the patients involved.

Cost evaluation
During the 12-month period, the potential cost of the intercepted medication errors to the French health insurance system was estimated at 92,907 €, with 69,248 € (74%) attributed to hospitalisation and 23,658 € (26%) to the cost of drugs in addition to the diagnosis-related groups (Table 6). Furthermore, if not intercepted, the medication errors described above would have led to 216 additional hospital days. The results from the evaluation by two physicians according to speciality are provided in Table 6, reflecting the divergence in physicians’ medical appreciation of medication errors and their clinical consequences.

Discussion
Our results demonstrate that medication errors occurred frequently at our hospital, at a rate of 5.2%, which is comparable to the rates reported in published literature, ranging from 0.4% to 31.9% [23-25]. The
significant relationship found between the rate of medication errors and month of the year is still unclear, as it cannot be accounted by the biannual rotation of residents occurring in May and November. Furthermore, error rates were lower in the haematology and medical oncology wards (\(p = 0.001\)), where the most antineoplastic chemotherapy was prescribed, suggesting that oncological experience was incremental in reducing the error risk. Indeed, the haematology and medical oncology wards are specialised in cancer treatment, while the pneumology and gastroenterology wards usually treat other diseases. In addition, in the haematology and medical oncology wards, residents and physicians generally attend a specific training program, including more detailed practical and theoretical approaches dedicated to cancer chemotherapy treatments. Incomplete prescriptions were found to be frequent and time-consuming for physicians and pharmacists, constituting a delaying factor in the setting up of therapy. Medication dose errors represented the second most common type of error in terms of frequency, with the dose difference being > 50% higher than the theoretical dose in 24.6% of cases (\(n = 41\)). These dose errors are considered to be the most dangerous for the patient. In our study, very few prescription medication errors actually reached the patient, due to the dedicated quality control system. Most prescription errors could possibly have been avoided by using a computerised chemotherapy prescribing system [26], but such a system is not available in all French hospitals. However, more recent publications highlighted the role played by computerised systems in the occurrence of other types of errors, demonstrating computers to be only a part of the ongoing process aimed to improve patient safety [27-29].

Only five administration errors (0.02%) were detected, which was lower than the rate reported in literature [30,31]. The pharmaceutical error rate (0.16%) appeared to

| Table 4 Descriptive analysis of antineoplastic dose errors |
|-----------------------------------------------------------|
| **Percentage of error** | **Underdosage** | **Overdosage** | **Frequency of drug prescriptions (%)** |
|-------------------------|-----------------|----------------|----------------------------------------|
|                         | < 10 [10-50]    | > 100          | < 10 [10-50] > 100                     | **Total** |
| Bevacizumab             | - - 2 - | - | - | - | - | 3 | 0.65 |
| Bleomycin               | - - - - | - | - | - | - | 3 | 3.1 |
| Bortezomib              | 1 - - - | - | - | - | - | 5 | 3.36 |
| Carboplatin             | 4 9 1 | - 5 | 14 | 2 | - | 35 | 2.66 |
| Cetuximab               | - - - - | - | - | - | - | 2 | 0.99 |
| Cisplatin               | - - - - | - | - | - | - | 2 | 3.23 |
| Cyclophosphamide        | 1 2 1 | - 1 | 2 | 1 | - | 8 | 6.31 |
| Cytarabine              | - 1 | - | - | - | - | - | 1 |
| Dacarbazine             | - - - | - | - | - | - | 1 | 1.71 |
| Docetaxel               | - - - | - | - | - | - | 2 | 2.69 |
| Doxorubicin             | - 1 | - | 2 | - | - | 1 | 4 |
| Drug in clinical trial  | - | - | - | - | - | - | 2 |
| Liposomal doxorubicin   | - - | - | - | 2 | - | - | 0.31 |
| Epirubicin              | - 1 | - | - | - | - | - | 1 |
| Etoposide               | 1 | 1 | - | 1 | - | 1 | 5 |
| Fluorouracil            | 4 | - | 4 | 9 | 1 | 19 | 12.1 |
| Gemcitabine             | 1 | - | - | - | 5 | 3 | 10 |
| Ifosfamide              | 2 | 2 | - | 2 | 2 | - | 8 |
| Irinotecan              | 1 | - | - | - | 1 | 1 | 1 |
| Methotrexate            | 1 | - | - | - | - | 1 | 2 |
| Oxaliplatin             | 1 | 2 | - | 1 | 7 | 1 | 13 |
| Paclitaxel              | 1 | - | - | - | 3 | - | 4 |
| Raltitrexed             | - - | - | - | - | 1 | - | 1 |
| Rituximab               | 2 | - | - | 4 | - | 7 | 8.21 |
| Trastuzumab             | 1 | 1 | - | - | - | - | 2 |
| Vinblastine             | - - | - | - | - | 1 | 1 | 3 |
| Vincristine             | - | 1 | - | 4 | 3 | - | 8 |
| Vindesine               | - | - | - | - | 1 | - | 1 |
| Vinorelbine             | - | - | - | - | 2 | 1 | 4 |

\(^1\) Percentage of error = (theoretical dose - incorrect dose)/theoretical dose *100
Figure 1 Percentages of medication errors by month of the year.

Table 5 Severity distribution of intercepted medication errors

| Potential severity according to the Medication Error Index (3) | Number of protocols with at least one error |
|---------------------------------------------------------------|--------------------------------------------|
|                                                               | Haematology | Oncology | Pneumology | Pharmacy | Total\(^2\) (% of erroneous prescription) |
| No consequences for the patient                               | a           | b        | c          | d        | e     | f     | g     |                               |
| An error avoided that would not cause patient harm            | 20          | 21       | 18         | 19       | 14    | 14    | 157   | 210                           |
| An error avoided that would require monitoring to confirm that it did not result in patient harm | 3           | 10       | 4          | 8        | 7     | 16    | 34    | 58                            |
| Total                                                         | 268         | 81.4%    |
| Temporary damage                                              |             |          |            |          |       |       |       |                               |
| An error avoided that could have contributed to temporary harm to the patient, requiring intervention | 6           | 0        | 9          | 8        | 9     | 4     | 0     | 18                            |
| An error avoided that could have contributed to temporary harm to the patient, requiring initial or prolonged hospitalisation | 14          | 12       | 13         | 6        | 6     | 1     | 0     | 26                            |
| Total                                                         | 44          | 13.4%    |
| Permanent damage                                              |             |          |            |          |       |       |       |                               |
| An error avoided that could have contributed to permanent patient harm | 7           | 7        | 1          | 2        | 0     | 0     | 0     | 8.5 (2.6%)                   |
| Compromised vital prognosis                                   |             |          |            |          |       |       |       |                               |
| An error avoided that could have required intervention necessary to sustain life | 0           | 0        | 2          | 2        | 1     | 0     | 0     | 2.5 (0.8%)                   |
| Patient death                                                 |             |          |            |          |       |       |       |                               |
| An error avoided that could have contributed to the patient’s death | 3           | 3        | 1          | 3        | 0     | 2     | 0     | 6 (1.8%)                     |
| Total                                                         | 53          | 53       | 48         | 48       | 37    | 37    | 191   | 329 (100%)                   |

1 including gastroenterology and radiotherapy
2 Total = (a+b)/2 + (c+d)/2 + (e+f)/2 +g
### Table 6 Assessment of the potential cost of medication errors

|                               | Haematology | Oncology¹ | Pneumology |
|-------------------------------|-------------|-----------|------------|
|                               | a           | b         | c          | d          | e           | f          | Total²    |
| Cost linked to new potential hospitalisation (€ 2008) | 7,908.5     | 5,354.2   | 3,614.3    | 844.9      | 0           | 0          | 8,861     |
| Cost linked to potential prolongation of hospitalisation (€ 2008) | 26,720.9    | 29,213.8  | 24,039.5   | 21,232.3   | 13,259.6    | 6,309.1    | 60,387.6  |
| Cost linked to drugs paid for in addition to the diagnosis-related groups (€ 2008) | 8,313.9     | 8,383.9   | 12,378.8   | 12,378.8   | 2,930.9     | 2,930.9    | 23,658.6  |
| **Total (€ 2008)**           | 42,943.3    | 42,951.9  | 40,032.6   | 34,456     | 16,190.5    | 9,240      | 92,907.2  |

¹ including gastroenterology and radiotherapy
² Total = (a+b)/2 + (c+d)/2 + (e+f)/2
be very low compared with a similar study focused on the preparation process (3.6% of pharmaceutical errors) [32] and also lower than another study using a totally computerised chemotherapy prescribing system (0.45%) [33]. Bibliographic data suggests that there was significant under-reporting of administration and pharmaceutical errors in our study, which may be explained by a number of factors, such as the fear of blame as well as the bureaucratic and time-consuming process for reporting incidents.

Our findings provide more precise information than previously available on the potential severity and clinical consequences of medication errors in terms of required monitoring, hospitalisation, and treatment. In our study, if medication errors had not been intercepted prior to administration, 13.4% would have caused temporary damage and 2.6% permanent injury, while 2.6% would have compromised the vital prognosis of the patient. The potential for fatal accidents still exists, with four to eight deaths being avoided by means of the collaborative medical and pharmaceutical teams. The dramatic consequences of antineoplastic medication errors are crucial given the nature of anticancer drug toxicity, the use of antineoplastics drugs in complex multiple-drug regimens, and the overall health status of cancer patients. In our study, the potential consequences of medication errors could not be established, but instead they were estimated by physicians, which was a difficult exercise as illustrated by the kappa score. Indeed, some toxicities, such as neurotoxicities, along with their impact on patient care are difficult to predict. Furthermore, the evaluations were arbitrary, as they did not take into account the measures adopted in case of immediate discovery of the medication errors.

To our knowledge, no studies to date have estimated the potential costs of antineoplastic medication errors. It was estimated that close to 100,000 € was saved in addition to 216 additional days of hospitalisation. Comparisons with other cost analysis studies are difficult, due to the differing methodologies, choices, and specific features of the health systems in various countries. In addition, our study was limited to antineoplastic chemotherapy, which in turn reduces its comparability, and our cost analysis took only into account hospital and medication costs arising for the French health insurance system. However, the cost of medication errors for the society as a whole is much higher, when considering the direct non-medical costs, such as patient transportation, home care, and housing fitting if necessary, and the indirect costs, like hiring home help, as well as the intangible costs, such as those relating to pain and suffering. In addition, it should be noted that the costs involved in the time spent by physicians, pharmacists, and nurses on the quality control system aimed at intercepting medication errors was not evaluated in our study, although an economic assessment of this issue appears warranted.

Conclusion
This study demonstrated that very few medication errors actually reached patients, although defects in the chemotherapy ordering process were frequent, with the potential to be dangerous and costly. Oncology was an area of particular risk due to the severity of medical consequences for the patient, as shown by the six potential deaths that were avoided. The potential costs related to medication errors were not negligible, being nearly 100,000 € over a 1-year time period, although this figure did not include indirect outpatient medical and other non-medical related costs. The dedicated quality control system was able to intercept most of the medication errors prior to administration. Such a chemotherapy control system, however, requires close cooperation between physicians, pharmacists, and nurses.

Our study highlighted the need for developing systematic preventive actions in order to reduce medication errors and improve quality of care. Electronic prescribing of antineoplastic chemotherapy appears to be the next step in the ongoing process of improving safety. Other complementary approaches, such as medication error reviews that allow for a collective and multidisciplinary error analysis, should also be implemented.

Acknowledgements and funding
We would like to acknowledge the medical, pharmaceutical, and nursing teams at the Centre Hospitaller Lyon Sud, Hospices Civils de Lyon, France. No direct funding was received for the study. The authors were personally salaried by their institutions during the period of writing, although no specific salary was set aside or given for writing the paper.

Author details
1Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Pierre Bénite - Université Lyon 1, École Doctorale Interdisciplinaire Sciences Santé, Lyon, France. 2Hospices Civils de Lyon, Groupement Hospitalier Sud, Department of Haematology, Pierre Bénite. Université Lyon 1, UMR5239 CNRS -ENS, Lyon, France. 3Université Lyon 1, EA 4129 « Santé Individu et Société », Lyon, France. 4Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Pierre Bénite, France. 5Hospices Civils de Lyon, Groupement Hospitalier Sud, Department of Haematology, Pierre Bénite, France. 6Hospices Civils de Lyon, Groupement Hospitalier Sud, Department of Oncology, Pierre Bénite. Université Lyon 1, EMR UCB/L/HCL 3738, Lyon, France. 7Hospices Civils de Lyon, Groupement Hospitalier Sud, Department of Oncology, Pierre Bénite, Lyon, France. 8Hospices Civils de Lyon, Groupement Hospitalier Sud, Department of Pneumology, Pierre Bénite, France. 9Hôpital d'Instructions des Armées Désenginettes, Department of pharmacy, Lyon - Université Lyon 1, École Doctorale Interdisciplinaire Sciences Santé, Lyon, France. 10Université Lyon 1, EMR UCB/L/HCL 3738, Lyon, France. 11Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Pierre Bénite - Université Lyon 1, EMR UCB/L/HCL 3738, Lyon, France.

Authors’ contributions
All authors participated in the study, read the manuscript, and provided their final approval.

Competing interests
The authors declare that they have no competing interests. No direct funding was received for this study. The authors were personally salaried by their institutions during the period of writing, although no specific salary was set aside or given for writing the paper.
References

1. Kohn LT, Corrigan JM, Donaldson MS: To err is human: Building a safer health system Washington DC: National Academy Press; 1999.

2. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lavehgers AG, Newhouse JP, Weiler PC, Hiatt HH: Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 1991, 324:370-376.

3. National coordinating council on medication error reporting and prevention. [http://www.nccmerp.org/aboutMedErrors.html].

4. Phillips J, Beam S, Breker A, Holquist C, Honig P, Lee LY, Pamer C: Retrospective analysis of mortalities associated with medication error. Am J Health Syst Pharm 2001, 58:1835-1834.

5. Klys M, Konopka T, Sclerosis W, Kawański P: Fatality involving vinblastine overdose as a result of a complex medical error. Cancer Chemother Pharmacol 2007, 59:89-95.

6. Al Fenayan A, Russell NA, Wolhals MA, Awada A, Scherban M: Cerebrospinal fluid lavage in the treatment of inadvertent intrathecal vincristine injection. Childs Nerv Syst 1999, 15:87-90.

7. Ettinger LJ: Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 1982, 50:444-450.

8. Chu G, Martin R, Shen YM, Baskett G, Sussman H: Massive cisplatin overdose by accidental substitution for carboplatin. Cancer 1993, 72:3707-3714.

9. Taouel G, Bécart-Robert A, Courpoin P, Hédouin V, Gossot D: Fatal accidental intrathecal injection of vincristine. J Forensic Sci 2006, 51:1166-1168.

10. Dettmeyer R, Deneve F, Becker A, Westerod OD, Madsen B: Fatal myelonecrophalopathy due to accidental intrathecal vincristine administration: a report of two cases. Forensic Sci Int 2001, 122:60-64.

11. Kwack EK, Kim DJ, Cho YK, Kwon IH, Sohn YK: Neural toxicity induced by accidental intrathecal vincristine administration. J Korean Med Soc 1999, 14:688-692.

12. Mortensen ME, Cecaluppo AJ, Lo WD, Egorn Mj, Batley R: Inadvertent intrathecal injection of daunorubin with fatal outcome. Med Pediatr Oncol 1992, 20:249-253.

13. ASHP Council on Professional Affairs: ASHP guidelines on preventing medication errors with antineoplastic agents. Am J Health Syst Pharm 2002, 59:1648-1668.

14. Cohen MR, Anderson RW, Attillo RM, Green L, Muller RJ, Pruemer JM: Preventing medication errors in cancer chemotherapy. Am J Health Syst Pharm 1996, 53:737-746.

15. Fischer DS, Alfano S, Knobf MT, Donovan C, Beaulieu N: Fatality involving vinblastine. J Forensic Sci 2006, 51:1166-1168.

16. Jacobson JO, Polovich M, MCNIF KK, Lefebvre KB, Cummings C, Gallo M, Bonelli KR, Conklin MR: American Society of Clinical Oncology: American society of clinical oncology/oncology nursing society chemotherapy administration safety standards. J Clin Oncol 2009, 27:3469-75.

17. Surbone A, Rowe M, Gallagher TH: Confronting medical errors in oncology and disclosing them to cancer patients. J Clin Oncol 2007, 25:1463-7.

18. Bates DW, Spell N, Cullen DJ, Berwick D, Laird N, Petersen LA, Small SD, Siewerts B, Leape LL: The cost of adverse drug events in hospitalized patients. JAMA 1997, 277:307-311.

19. Institute of Medicine. Report brief: Preventing medication errors National Academy Press, 2006 [http://iom.edu/~media/Files/Reports/2006/Preventing-Medication-Errors-Quality-Chasm-Series/medicationerrornew.ashx].

20. Methodological guide production of summaries of stay in medicine, surgery and obstetrics. Agence Technique de l’Information sur l’Hospitallisation. [http://www.aths.sante.fr/index.php?id=0024007/TEFF].

21. Arrêté du 27 février 2007 relatif aux ressources d’assurances maladies des établissements de santé exerçant une activité de médecine, chirurgie, obstétrique et odontologie. Jornal Officiel république française du 4 mars 2007 [http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000002712066&dateTexte=].

22. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.

23. Lesar TS, Brodland L, Stein DS: Factors related to errors in medication prescribing. JAMA 1997, 277:312-317.

24. Rubin G, George A, Chinn DJ, Richardson C: Errors in general practice: development of an error classification and pilot study of a method for detecting errors. Qual Saf Health Care 2003, 12:443-447.

25. Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M: Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer 2009, 124:722-728.

26. Grangeasse L, Fagnoni-Legat C, Chaigneau L, Medjoub M, Larosa F, Bracco-Nolin CH, Woronoff-Lemsi MC, Limat S: Computerized prescribing of standardized chemotherapy schedules: residual medication errors and pharmaceutical interventions. J Pharm Clin 2006, 25(1):33-38.

27. Shulman R, Singer M, Goldstone J, Bellingan G: Medication errors: a prospective cohort study of hand-written and computerised physician order entry in the intensive care unit. Crit Care 2005, 9:516-521.

28. Colpaert K, Claus B, Somers, A, Vandervoude K, Robays H, Decruyenaere J: Impact of computerized physician order entry on medication prescription errors in the intensive care unit: a controlled cross-sectional trial. Crit Care 2006, 10:R21.

29. Finkelstein JB: E-prescribing first step to improved safety. J Nat Cancer Inst 2006, 98:1763-1764.

30. Tricot T, Comette C, Limat S, Mourand JL, Becker M, Elsevent JP, Dupond JL, Jacquet M, Woronoff-Lemsi MC: Observational study of potential risk factors of medication administration errors. Pharm World Sci 2003, 25:264-268.

31. Tricot T, Comette C, Demoly P, Jacquet M, Barale F, Capellier G: Medication errors at the administration stage in an intensive care unit. Intensive Care Med 1999, 25:363-369.

32. Gruwez B, Renaud JF, Lecante V, Lopez I, Dauphin A: Analysis of a manufacturing process example for cytotoxicies in a hospital pharmacy. J Pharm Clin 2001, 20:145-148.

33. Limat S, Drouhin JP, Demesmay K, Tricot T, Jacquet M, Woronoff-Lemsi MC: Incidence and risk factors of preparation errors in a centralized cytotoxic preparation unit. Pharm World Sci 2001, 23:102-106.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/478/prepub

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit